研究者業績
基本情報
- 所属
- 藤田医科大学 大学院医療科学研究科 客員教授 (名古屋大学名誉教授)NPO 医薬品適正使用推進機構 理事長
- 学位
- 薬学博士(東北大学)
- J-GLOBAL ID
- 201101030936121945
- researchmap会員ID
- B000004803
- 外部リンク
藤田医科大学大学院医療科学研究科 客員教授
学歴
1968年3月岐阜薬科大学製薬学科卒業
1973年3月大阪大学大学院薬学研究科博士課程単位取得後中退
1977年12月東北大学にて博士号修得(薬学)
職歴
1973年 4月名城大学薬学部 助手
1978年10月~1981年5月米国ミシシッピー州立大学メディカルセンター 客員助教授
1982年 4月名城大学薬学部 講師
1984年 4月名城大学薬学部 助教授
1990年 1月名古屋大学大学院医学系研究科臨床情報学講座医療薬学分野・医学部附属病院薬剤部 教授・部長(併任)
2006年 1月特定非営利活動法人医薬品適正使用推進機構理事長
2007年 3月名古屋大学を定年退職
2007年 4月より名城大学大学院薬学研究科 薬品作用学研究室 教授
2012年 3月名城大学を定年退職
2012年 4月より名城大学薬学部寄附講座 地域医療薬局学講座特任教授
2015年 3月より名城大学薬学部 特任教授
2015年12月より藤田医科大学大学院保健学研究科(現 医療科学研究科) 客員教授
現在の主な研究分野:神経精神薬理学:精神疾患動物モデルの作成と新薬開発への応用、薬物依存、医薬品の適正使用についての研究
研究キーワード
31研究分野
5経歴
10-
2015年12月 - 現在
-
2015年4月 - 2016年3月
-
2011年4月 - 2015年3月
-
2007年 - 2011年
-
1990年 - 2007年
学歴
3-
1977年
-
1968年
委員歴
4-
2004年 - 現在
-
2001年 - 現在
-
1992年 - 現在
-
2008年 - 2010年
受賞
9-
2008年
-
2007年
-
2007年
-
2007年
-
2001年
論文
794-
Behavioural Brain Research 496 115832-115832 2026年1月
-
British Journal of Pharmacology 2025年12月21日Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress (CUMS) and were evaluated by behavioural, neurochemical and metabolic analysis. Key Results Health check‐up data showed increased sucrose intake in MDD patients. When mice received sucrose under CUMS, hyperactivity and aggression were attenuated, although social deficits or behavioural despair induced by CUMS persisted, and recognition memory was impaired. The behavioural changes were associated with dysfunction of the locus coeruleus‐prefrontal cortex circuit, caused by impaired noradrenaline release due to presynaptic α 2 ‐adrenoceptor upregulation, and postsynaptic α 1 ‐adrenoceptor and β 1 ‐adrenoceptor downregulation. α 2 ‐Adrenoceptor antagonism by atipamezole rescued behavioural changes induced by sucrose intake under CUMS, whereas α 2 ‐adrenoceptor agonism by guanfacine in CUMS mice mimicked these behavioural changes. Among the antidepressants, mirtazapine effectively increased noradrenaline release and rescued behavioural changes induced by sucrose intake under CUMS. Sucrose intake under CUMS induced peripheral hyperglycaemia and dysregulation of central glucose metabolism. Glucose transporter inhibition by phloretin rescued behavioural changes induced by sucrose intake under CUMS. Intracerebroventricular and systemic streptozotocin administration reproduced these behavioural changes and α 2 ‐adrenoceptor upregulation. Conclusions and Implications Our findings suggest that the observed behavioural changes are associated with dysfunction of the noradrenergic α 2 ‐adrenoceptor system induced by impaired glucose metabolism. These insights targeting the noradrenergic‐metabolic axis might be a new strategy for sugar‐induced depression subtypes.
-
Journal of Neurochemistry 169(11) 2025年11月20日ABSTRACT Psychiatric disorders such as major depressive disorder are closely linked to the intestinal environment, suggesting intestinal health may contribute to their prevention. Prebiotics, which enhance intestinal health, are promising candidates for preventing psychiatric disorders. 1‐Kestose (kestose), a type of prebiotics, has shown potential, but its effects on psychiatric disorders remain unclear. In this study, we investigated whether kestose prevents abnormal behaviors induced by social isolation (SI) stress and which underlies mechanisms of preventive effects. C57BL/6J male mice (3 weeks old) were divided into two groups: individually housed (SI) group and housed five mice per cage (GH) group. Each group received either a normal diet or a kestose diet (5% kestose) for 5 weeks daily until the end of the behavioral testing. Kestose prevented the SI‐induced abnormal behaviors including reduced sociality, impaired spatial recognition, and heightened anxiety, which were associated with suppressed microglial activation in the hippocampus. Kestose altered the diversity of gut microbiota and increased the abundance of Bacteroides sartorii . Furthermore, short‐chain fatty acids (SCFAs) such as butyric acid, acetic acid, and propionic acid, produced by intestinal microbiota, were increased after kestose supplementation. Positive correlations were observed between B. sartorii abundance and SCFA levels, suggesting that B. sartorii contributes to SCFA production. Notably, both B. sartorii and SCFAs were strongly associated with the abnormal behaviors by SI. These findings suggest that kestose prevents SI‐induced abnormal behaviors by modulating gut microbiota, particularly B. sartorii , through an increase of SCFA production. Taken together, kestose could be used as a promising prebiotic intervention for psychiatric disorders. image
-
European Journal of Pharmacology 178407-178407 2025年11月
-
Pharmacological Research 221 107986-107986 2025年11月
MISC
950-
JOURNAL OF PHARMACOLOGICAL SCIENCES 94 33P-33P 2004年
-
Drug News Perspect. 17 1-4 2004年
-
Ann. NY Acad. Sci. 1025 198-204 2004年
-
J. Neurochem. 91 308-317 2004年 査読有り
-
Ann. NY Acad. Sci. 1025 274-278 2004年 査読有り
-
Ann. NY Acad. Sci. 1025 236-241 2004年 査読有り
-
Proc. Natl. Acad. Sci. USA. 101 3650-3655-3555 2004年 査読有り組織プラスミノーゲン活性化因子/プラスミンシステムがドパミン遊離を制御することにより、モルヒネの報酬効果に関与していることを見出した。
-
Eur. J. Pharmacol. 486 151-161 2004年 査読有り
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 23(6) 251-251 2003年12月25日
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 23(6) 280-280 2003年12月25日
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 23(6) 317-317 2003年12月25日
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 23(6) 281-281 2003年12月25日
-
Journal of toxicological sciences 28(4) 315-315 2003年10月31日
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 23(5) 187-196 2003年10月25日
-
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 23(5) 211-217 2003年10月25日
-
医療薬学 29(5) 575-580 2003年10月10日In order to carry out effective warfarin treatment and to avoid unnecessary adverse reactions, patients need to recognize the importance of drug compliance, food-drug interaction, drug-drug interaction, and matters that require attention in daily life. We therefore have conducted a "Warfarin Classroom" since April 2000 to provide proper information about warfarin to outpatients. We evaluated how did "Warfarin Classroom" changed both the knowledge and recognition in these patients using a scoring system. The number of subjects participating in this study was 136 (110 males, 26 females, avera...
-
Japanese Journal of Neuropsychopharmacology 23(4) 179-182 2003年8月
-
Molecular psychiatry 8(8) 752-65 2003年8月Nociceptin (also called orphanin FQ) is an endogenous heptadecapeptide that activates the opioid receptor-like 1 (ORL1) receptor. Nociceptin system not only affects the nociception and locomotor activity, but also regulates learning and memory in rodents. We have previously reported that long-term potentiation and memory of ORL1 receptor knockout mice are enhanced compared with those in wild-type mice. Here, we show the neuronal mechanism of nociceptin-induced modulation of learning and memory. Retention of fear-conditioned contextual memory was significantly enhanced in the ORL1 receptor knockout mice without any changes in cued conditioned freezing. Inversely, in the wild-type mice retention of contextual, but not cued, conditioning freezing behavior was suppressed by exogenous nociceptin when it was administered into the cerebroventricle immediately after the training. ORL1 receptor knockout mice exhibited a hyperfunction of N-methyl-D-aspartate (NMDA) receptor, as evidenced by an increase in [3H]MK-801 binding, NMDA-evoked 45Ca2+ uptake and activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) activity and its phosphorylation as compared with those in wild-type mice. The NMDA-induced CaMKII activation in the hippocampal slices of wild-type mice was significantly inhibited by exogenous nociceptin via a pertussis toxin-sensitive pathway. However, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor GluR1 subunit at Ser831 and Ser845, and NMDA receptor subunit NR2B at Thr286 were phosphorylated similarly after NMDA receptor stimulation in both type of mice. The expressions of GluR1 and GluR2 also did not change, but the levels of polysialylated form of neuronal cell adhesion molecule (N-CAM) were reduced in the ORL1 receptor knockout as compared with wild-type mice. These results suggest that nociceptin system negatively modulates learning and memory through the regulation of NMDA receptor function and the expression of N-CAM.
-
日本アルコール・薬物医学会雑誌 = Japanese journal of alcohol studies & drug dependence 38(3) 184-185 2003年6月28日
-
医療薬学 29(3) 318-322 2003年6月10日Doses of tacrolimus less than the standard dose (0.5mg) have often been prescribed for pediatric transplant patients. When preparing 0.1mg tacrolimus in a package, 13mg (contain 0.1mg tacrolimus) was used with a 0.5mg Prograf【○!R capsule (the total amount of 65mg), and then it was packaged by hand. However, it is difficult to prepare such drugs for many transplant patients, since this method is very complicated. Therefore, we examined how to prepare low dose packages of tacrolimus package easily and correctly without making any packaging errors. To reduce any preparation errors, the bulk of...
-
医療薬学 29(3) 323-329 2003年6月10日In general, medical staff members do their utmost to select appropriate medicines for each patient whenever possible. When choosing medicines, pharmacists have to provide medical staff members and patients with high quality information. However, it is often difficult to select the optimal medicine for patients. When physicians in Intensive Care Unit (ICU) and chief physicians select medication, how do they obtain mutual consent, and what kind of drugs are readily provided by mutual agreement? We tried to investigate this point using a questionnaire against given to both physicians and chief...
-
日本薬学会年会要旨集 123rd(1) 138 2003年3月5日
-
日本薬学会年会要旨集 123rd(1) 139 2003年3月5日
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 91 195P-195P 2003年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 91 199P-199P 2003年
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 91 194P-194P 2003年
-
Mol. Psychiat. 8 407-412 2003年 査読有り
書籍等出版物
14講演・口頭発表等
13-
日本医療薬学会年会講演要旨集 2010年10月25日
共同研究・競争的資金等の研究課題
40-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2020年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2019年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(B) 2017年4月 - 2022年3月




